September 18, 2019 / 5:55 AM / 3 months ago

BRIEF-Erytech Pharma H1 Net Loss Widens To 29.3 Million Euros

Sept 18 (Reuters) - ERYTECH PHARMA:

* REPORTED ON TUESDAY H1 NET LOSS EUR 29.3 MLN VS LOSS EUR 19.0 MLN YEAR AGO

* H1 TOTAL OPERATING LOSS EUR 30.2 MLN VS LOSS EUR 21.9 MLN YEAR AGO

* DR. JEAN PAUL KRESS APPOINTED AS CHAIRMAN

* TRYBECA1, PHASE 3 TRIAL FOR ERYASPASE IN SECOND LINE PANCREATIC CANCER, PROGRESSING ON PLAN

* CASH POSITION OF EUR 94.5 MILLION AT THE END OF JUNE

Source text for Eikon:

Further company coverage:

Gdynia Newsroom

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below